--- title: "Abivax SA (ABVX) news: offering" url: "https://aibio.space/companies/abivax/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "ABVX offering news: Abivax launches $600,000,000 offering of American Depositary Shares. Abivax SA (EURONEXT: ABVX), France." --- ABVX Abivax SA EURONEXT · France # Abivax SA (ABVX) news ABVX offering news Financings · 2026-06-30 ## [Abivax launches $600,000,000 offering of American Depositary Shares](https://aibio.space/news/abivax-launches-600-000-000-offering-american-depositary-shares/) Abivax's preliminary supplement of June 30, 2026 described a $600,000,000 offering. The final supplement priced 6,400,000 ADSs at $125.0000 each, $800,000,000 in all, one day after the company announced Phase 3 maintenance results. ## Latest Abivax SA news 1. 2025-09-08 Distress [Abivax expects cash into Q4 2027 after $747.5 million gross offering](https://aibio.space/news/abivax-expects-cash-q4-2027-after-747-5-million-gross-offering/) Abivax reported a first-half net loss of EUR 100.8 million and negative shareholders' equity of EUR 48.3 million at June 30, 2025, before a July US offering and several note conversions. The company now says its cash lasts into the fourth quarter of 2027. ## Abivax SA at a glance - **Ticker**: ABVX - **Listing**: EURONEXT - **Country**: France - **Cash, Dec 31, 2025**: €538.1 million ### Related companies - [Boiron SA](https://aibio.space/companies/boiron/) EURONEXT: BOI - [Biophytis SA](https://aibio.space/companies/biophytis/) EURONEXT: ALBPS - [AB Science SA](https://aibio.space/companies/science/) EURONEXT: AB - [THX Pharma](https://aibio.space/companies/thx-pharma/) EURONEXT: ALTHX - [Gensight Biologics SA](https://aibio.space/companies/gensight-biologics/) EURONEXT: SIGHT - [Inventiva SA](https://aibio.space/companies/inventiva/) EURONEXT: IVA - [Valbiotis SA](https://aibio.space/companies/valbiotis/) EURONEXT: ALVAL - [Sanofi SA](https://aibio.space/companies/sanofi/) EURONEXT: SAN ### Also on EURONEXT - [Malin Corporation](https://aibio.space/companies/malin/) MLC - [OSE Immunotherapeutics SA](https://aibio.space/companies/ose-immunotherapeutics/) OSE - [Oxurion NV](https://aibio.space/companies/oxurion/) OXUR - [Hyloris Pharmaceuticals SA](https://aibio.space/companies/hyloris-pharmaceuticals/) HYL - [MedinCell SA](https://aibio.space/companies/medincell/) MEDCL - [Advicenne SA](https://aibio.space/companies/advicenne/) ALDVI ## What Abivax SA does Abivax SA is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases, with an initial focus on inflammatory bowel diseases, including ulcerative colitis and Crohn's disease. Its lead drug candidate, obefazimod, is designed to enhance expression of the microRNA miR-124, which the company describes as a natural regulator of the inflammatory response. Obefazimod is in Phase 3 clinical development for moderately to severely active ulcerative colitis. The company initiated a Phase 2b clinical trial in patients with Crohn's disease in the fourth quarter of 2024. Abivax is also evaluating potential combination therapy opportunities in IBD, and it reports preclinical combination data with etrasimod in a mouse model of IBD. It is strengthening its development portfolio with follow-on compounds based on its miR-124 platform and by assessing external early drug candidates in IBD. The company was incorporated as a société anonyme under the laws of France on December 4, 2013. Its shares trade on Euronext Paris and its ADSs are listed on the Nasdaq Global Market. | Product or program | What it is | Stage | |---|---|---| | Obefazimod (ulcerative colitis) | miR-124 enhancer for moderately to severely active ulcerative colitis | Phase 3 | | Obefazimod (Crohn's disease) | miR-124 enhancer for Crohn's disease | Phase 2b | | miR-124 follow-on compounds | New candidates generated from the miR-124 enhancer library | | Summarised from the company's [20-F filed Mar 23, 2026](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm). ## Abivax SA annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [€177.8 million](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/) | [€146.5 million](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/) | | Net income (loss) | [-€336.1 million](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/) | [-€176.2 million](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/) | | Cash from operations | [-€161.1 million](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/) | [-€154.1 million](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/) | | Cash and equivalents | [€516.7 million](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/) | [€144.2 million](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/) | | Short-term investments | [€21.4 million](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/) | [€7.6 million](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/) | Latest balance sheet, Dec 31, 2025 (20-F): cash and equivalents €516.7 million, plus short-term investments of €21.4 million, €538.1 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Abivax SA Has Abivax SA raised money recently? Our latest story on this, dated Jun 30, 2026: "Abivax launches $600,000,000 offering of American Depositary Shares". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/abivax-launches-600-000-000-offering-american-depositary-shares/). What is the ticker symbol of Abivax SA? Abivax SA trades under the ticker ABVX on EURONEXT. Where is Abivax SA listed? Abivax SA is listed on EURONEXT. Our directory also records these other listings: DUS:2X1; FWB:2X1; GETTEX:2X1; HAM:2X1; HAN:2X1; LS:A14UQC; LSE:0RA9; LSX:A14UQC; MUN:2X1; NASDAQ:ABVX; SWB:2X1; TRADEGATE:2X1; VIE:ABVX; XETR:2X1. What is the SEC CIK of Abivax SA? The SEC Central Index Key (CIK) for Abivax SA is 1956827. Its filings are on SEC EDGAR. How many shares does Abivax SA have outstanding? 78,536,412 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-03-23. Which country or territory is Abivax SA listed under? Our directory records Abivax SA under France. What does Abivax SA do? Our directory classifies Abivax SA as: Biopharma / pharmaceutical profile checked. This is a directory classification, not a description of the pipeline. What is the ISIN of Abivax SA? The ISIN recorded for Abivax SA is FR0012333284. Does aibio.space cover Abivax SA? aibio.space lists Abivax SA among 2,820 public biotech companies and publishes its news here as stories appear. Where is Abivax SA incorporated? SEC records list its state or country of incorporation as I0. What does Abivax SA develop? Abivax SA is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases, with an initial focus on inflammatory bowel diseases, including ulcerative colitis and Crohn's disease. Its lead drug candidate, obefazimod, is designed to enhance expression of the microRNA miR-124, which the company describes as a natural regulator of the inflammatory response. What is Obefazimod (ulcerative colitis) from Abivax SA? Obefazimod (ulcerative colitis): miR-124 enhancer for moderately to severely active ulcerative colitis Stage: Phase 3. What is Obefazimod (Crohn's disease) from Abivax SA? Obefazimod (Crohn's disease): miR-124 enhancer for Crohn's disease Stage: Phase 2b. What is the latest Abivax SA (ABVX) stock news? Our latest story on Abivax SA, dated Jun 30, 2026: "Abivax launches $600,000,000 offering of American Depositary Shares". Abivax's preliminary supplement of June 30, 2026 described a $600,000,000 offering. The final supplement priced 6,400,000 ADSs at $125.0000 each, $800,000,000 in all, one day after the company announced Phase 3 maintenance results. [Source](https://aibio.space/news/abivax-launches-600-000-000-offering-american-depositary-shares/). How much cash does Abivax SA have? From our story of Jun 30, 2026: The repurchase, agreed May 4, 2026, cost $90.0 million, $45.0 million in cash and $45.0 million in shares. [Source](https://aibio.space/news/abivax-launches-600-000-000-offering-american-depositary-shares/). ## Investor discussion: Abivax SA Members talk about Abivax SA (ABVX). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Abivax SA, newest first. Each line links the filing it comes from. 1. 2026-06-30 Financings Filed a final prospectus for a securities offering. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1956827/000119312526290817/d111359d424b5.htm) 2. 2026-05-20 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000017/exhibit991-pressreleasefor.htm) 3. 2026-05-07 Financings Reported a financing. SEC Form 424B7. [Source](https://www.sec.gov/Archives/edgar/data/1956827/000119312526210978/d55760d424b7.htm) 4. 2025-12-15 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1956827/000195682725000035/item991-pressreleaseq32025.htm) 5. 2025-09-08 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1956827/000195682725000031/item991-pressreleaseh12025.htm) 6. 2025-07-23 Financings Filed a final prospectus for a securities offering. SEC Form F-3ASR. [Source](https://www.sec.gov/Archives/edgar/data/1956827/000119312525163402/d944622df3asr.htm) 7. 2025-06-11 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1956827/000195682725000024/exhibit991-pressreleasefor.htm) 8. 2024-11-19 Financings Reported a financing. SEC Form F-3. [Source](https://www.sec.gov/Archives/edgar/data/1956827/000119312524261713/d859699df3.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open EURONEXT:ABVX on TradingView](https://www.tradingview.com/symbols/EURONEXT-ABVX/). ## SEC filings and registration - **SEC name**: Abivax S.A. - **CIK**: 1956827 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: ABVX (Nasdaq), AAVXF (OTC) - **State or country of incorporation**: I0 - **Fiscal year ends**: December 31 - **Filer category**: Accelerated filer
Emerging growth company - **Business address**: 7 BD HAUSSMANN, PARIS - **Phone**: 01 53 83 09 63 - **Shares outstanding**: 78,536,412 as of 2025-12-31 (20-F filed 2026-03-23) ### Recent filings (8-K and 6-K are the company's own announcements) - [6-K](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000027/abvx-20260630.htm) filed 2026-09-21 - [6-K](https://www.sec.gov/Archives/edgar/data/1956827/000119312526294514/d108401d6k.htm) filed 2026-07-02 - [424B5](https://www.sec.gov/Archives/edgar/data/1956827/000119312526294491/d111359d424b5.htm) filed 2026-07-02 - [424B5](https://www.sec.gov/Archives/edgar/data/1956827/000119312526290817/d111359d424b5.htm) filed 2026-06-30 - [6-K](https://www.sec.gov/Archives/edgar/data/1956827/000119312526288752/d110874d6k.htm) filed 2026-06-29 - [6-K](https://www.sec.gov/Archives/edgar/data/1956827/000119312526252360/d98688d6k.htm) filed 2026-06-02 - [6-K](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000022/abvx-20260331.htm) filed 2026-05-22 - [6-K](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000017/a6-kcoverpagex060925pressr.htm) filed 2026-05-20 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001956827), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Abivax SA is a public biotech or pharmaceutical company listed on EURONEXT under the ticker ABVX, recorded under France. The directory classifies it as Biopharma / pharmaceutical profile checked. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Abivax SA - **Ticker**: ABVX - **Listing**: EURONEXT - **Country or territory**: France - **Business scope**: Biopharma / pharmaceutical profile checked - **ISIN**: FR0012333284 - **Other listed symbols**: DUS:2X1; FWB:2X1; GETTEX:2X1; HAM:2X1; HAN:2X1; LS:A14UQC; LSE:0RA9; LSX:A14UQC; MUN:2X1; NASDAQ:ABVX; SWB:2X1; TRADEGATE:2X1; VIE:ABVX; XETR:2X1 - **Last quote in directory**: 2026-10-22 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/EURONEXT-ABVX/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/abivax/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Abivax SA (ABVX) news: offering", 2026-10-31, https://aibio.space/companies/abivax/